Pediatric nephrology (Berlin, Germany) · 2025
Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Yanyan, Sheng Aiqin, Lin Qian, Cen Kuankuan, Zhao Manli, Feng Chunyue, Fu Haidong, Mao Jianhua
Аннотация
BACKGROUND: Recent investigations have indicated that telitacicept significantly diminishes proteinuria levels in adult patients diagnosed with IgA nephropathy (IgAN). The therapy has been correlated with a substantial reduction in galactose-deficient IgA1 (Gd-IgA1) levels. The present study endeavors to clarify the efficacy and safety profile of telitacicept in the treatment of IgAN among pediatric patients.
METHODS: This study is a retrospective, observational, single-center research on 12 pediatric patients with IgAN treated with telitacicept as adjunctive therapy, mainly via weekly subcutaneous injections at 2.5 mg/kg, up to a maximum of 160 mg. During telitacicept treatment, ACEI use was maintained, and immunosuppressive doses were gradually reduced.
RESULTS: A total of 12 patients with a mean age of 11.75 years were enrolled. The median follow-up duration post-telitacicept initiation was 9 months. The median 24 h urinary proteinuria decreased from 0.98 (0.5, 9.8) g/1.73 m2 at baseline to 0.36 (0.08, 2.49) g/1.73 m2 at month 12. At the final follow-up, 7 patients (58.3%) achieved complete remission. During the follow-up period, routine urinalysis demonstrated a significant improvement in urinary red blood cell counts for all patients. No serious adverse events (AEs) were reported in any patient during treatment with telitacicept.
CONCLUSIONS: Telitacicept has exhibited both effectiveness and safety in the treatment of children diagnosed with IgAN.
METHODS: This study is a retrospective, observational, single-center research on 12 pediatric patients with IgAN treated with telitacicept as adjunctive therapy, mainly via weekly subcutaneous injections at 2.5 mg/kg, up to a maximum of 160 mg. During telitacicept treatment, ACEI use was maintained, and immunosuppressive doses were gradually reduced.
RESULTS: A total of 12 patients with a mean age of 11.75 years were enrolled. The median follow-up duration post-telitacicept initiation was 9 months. The median 24 h urinary proteinuria decreased from 0.98 (0.5, 9.8) g/1.73 m2 at baseline to 0.36 (0.08, 2.49) g/1.73 m2 at month 12. At the final follow-up, 7 patients (58.3%) achieved complete remission. During the follow-up period, routine urinalysis demonstrated a significant improvement in urinary red blood cell counts for all patients. No serious adverse events (AEs) were reported in any patient during treatment with telitacicept.
CONCLUSIONS: Telitacicept has exhibited both effectiveness and safety in the treatment of children diagnosed with IgAN.